FDA批准NEREUS 运动疾病, 将试验中呕吐减少50%以上。 FDA approves NEREUS® for motion sickness, reducing vomiting by over 50% in trials.

美国食品和药物管理局批准了NEREUS® (流药),这是40多年来首个新的运动恶心治疗方法,用于预防成年人的吐. The FDA has approved NEREUS® (tradipitant), the first new motion sickness treatment in over 40 years, for preventing vomiting in adults. 根据包括现实世界船研究在内的三项临床试验,该药物与安慰剂相比,显著降低了呕吐率,减少了50%以上的风险。 Based on three clinical trials, including real-world boat studies, the drug significantly reduced vomiting rates compared to placebo, with over 50% risk reduction. 常见副作用包括共鸣和疲劳。 Common side effects include somnolence and fatigue. 它可能妨碍驾驶或机械操作,特别是与其他CNS抑制剂一起。 It may impair driving or machinery operation, especially with other CNS depressants. 怀孕和哺乳期间的安全仍不确定。 Safety during pregnancy and breastfeeding remains uncertain. 该药物由旺达制药公司开发,预计不久将推出,预计美国年销售高峰将超过1亿美元。 The drug, developed by Vanda Pharmaceuticals, is expected to launch soon, with projected peak U.S. sales exceeding $100 million annually.